Study of Secutrelvir in Participants With COVID-19
← catalyst calendarNCT07746544 · readout in 346 d
Sponsored by Shionogi (industry) · 4507.T — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
1,200estimated
Sites
1
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-20 | estimated | When the study began enrolling |
| Primary completion | 2027-07-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- COVID-19
Interventions
- Drug: Secutrelvir — also filed as S-892216
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFTime to First Resolution of 14 Protocol-defined Symptoms of COVID-19 Through Day 21
measured Baseline through Day 21
Permalink · 4507.T's whole pipeline · Catalyst calendar · Every registered study · What changed